Massive Transfusion Protocol – Evidence‑Based Recommendations
1. Protocol Activation and Initial Response
- Activate the massive transfusion protocol immediately when massive hemorrhage is declared (anticipated loss of 1–1.5 blood volumes or hemodynamic instability with systolic BP < 90 mmHg or HR > 110 bpm) 1.
- Simultaneously mobilize clinical, laboratory and logistic resources at activation 1.
2. Immediate Hemorrhage Control
- Prioritize control of obvious bleeding with direct pressure, tourniquets or hemostatic dressings before initiating transfusion 1.
- Obtain large‑bore intravenous access; if peripheral access fails, use intra‑osseous or surgical venous access 1.
- Deliver high‑flow oxygen to all patients 1.
3. Blood Component Administration
3.1 Red Blood Cells
- Begin transfusion with uncross‑matched O‑negative blood only when immediate transfusion is required; switch to group‑specific blood without antibody screening, then to cross‑matched units as soon as possible 1.
- Use component administration sets equipped with 170–200 µm filters for all blood products 4.
3.2 Platelets
- Use a dedicated clean giving set for platelet transfusion; re‑using a set previously used for red cells can cause platelet adhesion and reduce dosing efficacy 5.
3.3 Fresh Frozen Plasma (FFP)
- Give early FFP at 15 mL/kg when massive hemorrhage is anticipated to prevent the development of coagulopathy 1.
- If fibrinogen < 1 g/L or PT/aPTT > 1.5 × normal, this indicates established hemostatic failure and predicts microvascular bleeding 1; correction then requires > 15 mL/kg FFP 1.
3.4 Fibrinogen Replacement
- Achieve rapid fibrinogen repletion with fibrinogen concentrate or cryoprecipitate, targeting fibrinogen > 1.5 g/L 1.
- Measure fibrinogen using the Clauss method; derived fibrinogen values are misleading and should be avoided 3.
3.5 Platelet Targets
- Maintain a minimum platelet count of ≥ 75 × 10⁹/L in massive hemorrhage 1.
- For major surgery without active bleeding, keep platelets > 50 × 10⁹/L 2; for neurosurgery or posterior‑segment ophthalmic surgery, aim for > 100 × 10⁹/L 2.
3.6 Balanced Resuscitation Ratios
- Use a 1:1:1 ratio of red cells : FFP : platelets for the most severely traumatized patients, mirroring military practice, to prevent dilutional coagulopathy 1.
4. Equipment and Warming
4.1 Blood and Fluid Warming
- Warm all intravenous fluids ≥ 500 mL and all blood components to 37 °C for adult patients undergoing elective or emergency surgery under general or regional anesthesia 5.
- Employ approved blood‑warming devices with a visible thermometer and audible alarm; never use improvised warming methods (e.g., warm water, microwave) 8.
- The greatest thermal benefit is achieved by warming stored red cells (4 °C) rather than platelets (22 ± 2 °C) or thawed plasma/cryoprecipitate (37 °C) 8.
4.2 Rapid Infusion Devices
- Deploy rapid‑infusion devices capable of 6–30 L/h when large volumes must be delivered quickly; these devices typically incorporate integrated blood‑warming units 5.
- Use only manufacturer‑verified, CE‑marked devices and monitor delivered volume continuously 5.
4.3 Pressure Devices
- External pressure infusion devices can deliver a unit of red cells within minutes and should be reserved for emergencies with large‑gauge venous access 5.
5. Pharmacologic Adjuncts
5.1 Tranexamic Acid
- Administer 1 g tranexamic acid over 10 min followed by a second 1 g over 8 h when accelerated fibrinolysis is suspected or confirmed (identified by elevated D‑dimer, fibrin‑degradation products, or point‑of‑care viscoelastic testing) 8.
- Adverse events are rare in massive hemorrhage; use caution with repeat dosing in renal impairment and avoid use in subarachnoid hemorrhage due to risk of cerebral edema 10.
5.2 Prothrombin Complex Concentrate (PCC)
- For rapid reversal of vitamin K antagonists in life‑threatening bleeding, give PCC 25 IU/kg together with 5–10 mg intravenous vitamin K; re‑check INR after 30 min 2.
- Be aware of thrombotic and hypersensitivity risks associated with PCC 2.
6. Laboratory Monitoring
- Obtain baseline labs immediately: CBC, PT, aPTT, Clauss fibrinogen (avoid derived values), and type‑and‑crossmatch 3.
- Use point‑of‑care viscoelastic testing (TEG/ROTEM) when available to guide hemostatic therapy 3.
- Continuously monitor coagulation parameters, hemoglobin, and arterial blood gases in critical care 3.
7. Resuscitation Strategy
7.1 Permissive Hypotension
- Do not aim to normalize blood pressure before definitive hemorrhage control, as this may worsen bleeding 3. Clinical perfusion assessment (consciousness, speech, palpable pulse) guides adequacy 3.
7.2 Fluid Management
- Minimize crystalloid use to avoid dilutional coagulopathy 3; defer vasopressors until bleeding is controlled 3.
7.3 Cell Salvage
- Employ intra‑operative cell salvage in all massive hemorrhage cases; use a 40‑µm filter if bone fragments contaminate the salvaged blood 5.
8. Post‑Resuscitation Management
- Admit patients to a critical‑care unit for continuous monitoring 3.
- Initiate standard venous thromboprophylaxis as soon as hemostasis is secured, recognizing the pro‑thrombotic state after massive hemorrhage 1.